Pharma Mar (FRA:PMRA) EBIT: €62.2 Mil (TTM As of Mar. 2026)


FRA:PMRA Pharma Mar SA FRA:PMRA
83 GF Score
Price €68.65
GF Value €83.37
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar EBIT?

Pharma Mar FRA:PMRA +0.88% 83 EBIT is €62.2 Mil as of Mar. 2026. GuruFocus rates FRA:PMRA with a GF Score™ of 83/100 and a GF Value™ of €83.37 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Pharma Mar's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €0.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €62.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pharma Mar's annualized ROC % for the quarter that ended in Mar. 2026 was 1.34%. Pharma Mar's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pharma Mar's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.52%.

Pharma Mar  (FRA:PMRA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pharma Mar's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=2.488 * ( 1 - 4.07% )/( (183.841 + 173.582)/ 2 )
=2.3867384/178.7115
=1.34 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=395.081 - 44.017 - ( 167.223 - max(0, 93.878 - 283.415+167.223))
=183.841

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=385.261 - 43.826 - ( 167.853 - max(0, 89.226 - 273.451+167.853))
=173.582

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Pharma Mar's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2.488/( ( (60.15 + max(34.691, 0)) + (59.657 + max(29.433, 0)) )/ 2 )
=2.488/( ( 94.841 + 89.09 )/ 2 )
=2.488/91.9655
=2.71 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(39.054 + 50.635 + 26.148) - (44.017 + 0 + 37.129)
=34.691

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(39.95 + 53.119 + 12.529) - (43.826 + 0 + 32.339)
=29.433

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pharma Mar's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=62.211/1127.424
=5.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar EBIT Related Terms

Pharma Mar EBIT Historical Data

* Premium members only.

The historical data trend for Pharma Mar's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar EBIT Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.50 46.17 -1.21 14.45 62.11

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.09 24.15 -3.96 41.40 0.62

FRA:PMRA vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Pharma Mar's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Mar EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharma Mar's EV-to-EBIT falls into.


FRA:PMRA
83GF Score
Pharma Mar SA FRA:PMRA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €62.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €62.2 Mil mean?
Pharma Mar (FRA:PMRA) has a EBIT of €62.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pharma Mar.
Is Pharma Mar's EBIT too high?
Pharma Mar's current EBIT is €62.2 Mil. Overall, Pharma Mar has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's EBIT compare to VRTX and REGN?
Pharma Mar's EBIT of €62.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pharma Mar. Pharma Mar's current EBIT is €62.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (FRA:PMRA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.37, compared to a current price of €68.65 — trading 17.7% below its estimated fair value. The current EBIT is €62.2 Mil. Pharma Mar's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pharma Mar (FRA:PMRA), the current EBIT is €62.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (FRA:PMRA) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of €68.65 is trading 17.7% below its estimated GF Value™ of €83.37. GuruFocus considers Pharma Mar to be Modestly Undervalued.

Key valuation signals for FRA:PMRA:

  • EBIT: €62.2 Mil
  • GF Value™: €83.37 vs. price of €68.65 (17.7% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the FRA:PMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
83GF Score

Get the complete analysis for FRA:PMRA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.65
Price
€83.37
GF Value